Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma

DSpace Repository

Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma

Author: Ruf, Benjamin; Berchtold, Susanne; Venturelli, Sascha; Burkard, Markus; Smirnow, Irina; Prenzel, Tanja; Henning, Stefan W.; Lauer, Ulrich M.
Tübinger Autor(en):
Ruf, Benjamin
Berchtold, Susanne
Venturelli, Sascha
Burkard, Markus
Smirnow, Irina
Lauer, Ulrich Manfred
Published in: Molecular Therapy - Oncolytics (2015), Bd. 2, Article UNSP 150019
Verlagsangabe: Nature Publishing Group
Language: English
Full text: http://dx.doi.org/10.1038/mto.2015.19
ISSN: 2372-7705
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)